Antibiotics Flashcards

(138 cards)

1
Q

natural penicillins

A

penicillin G

penicillin V

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

anti-staph penicillins

A

oxacillin
dicloxacillin
nafcilin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

aminopenicillins

A

ampicillin

amoxicillin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

anti-pseudomonal penicillins

A

tricarcillin

piperacillin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

1st gen cephalosporins

A

cefazolin

cephalexin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

2nd gen cephalosporins

A

cefoxitin

cefuroximne

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

3rd gen cephalosporins

A

ceftriaxone

ceftazimine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

4th gen cephalosporin

A

cefepime

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

carbapenems

A

imipenem/cilastatin
meropenem
ertapenem

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

b-lactamase inhibitors

A

ampicillin-subactam
amoxicillin-clavulanic acid
piperacillin-taxobactam

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

glycopeptides

A

vancomycin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

fluroquinolones

A

ciprofloaxin
levofloxacin
moxifloxacin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

aminoglycosides

A

amikacin
tobramycin
gentamicin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

tetracyclines and glyclcyclines

A

minocycline
doxycycline
tigecycline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

macrolides and ketolides

A

clarithomycin
axithromycin
telithromycin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

lincosamides

A

clindamycin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

streptogramins

A

quinipristin/dalfopristin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

oxazolidinoes

A

linezolid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

polymyxins

A

colistin

polymyxin B

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

lipopeptides

A

daptomycin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

sulfonamides and trimethoprim

A

sulfamethozazole/trimiethoprim

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

urinary tract antiseptics

A

methenamine

nitrofurantoin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

MIC

A

minimum inhibitory concentration
lowest concentration of drug required to inhibit growth
determined by CLSI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

tests to determine MIC

A

dilution
disk diffusion
optical diffusion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
bacteriostatic
arrests growth and replication of bacteria
26
bactericidal
kills bacterial
27
targets of antimicrobials
``` cell wall synthesis cell membrane synthesis synthesis of 30S and 50S ribosome subunits nucleic acid metabolism fnx of topoisomerases folate synthesis ```
28
resistance mechansims
- reduced entry of antibiotic into pathogen - enhanced export of antibiotic by efflux pumps - release of microbial enzymes which destroy antibiotic - alteration of microbial proteins that transform pro-drugs to effective drugs - alteration of target proteins - development of alternative pathways to those inhibited by antibiotics
29
classification based on
``` class and spectrum of microorganism it kills biochemical pathway it interferes with chemical structure ```
30
inhibitors of cell wall synthesis
``` penicillins cephalosporins carbapenems monobactams glycopeptides ```
31
B-lactams MOA
structural analogs of D-Ala-D-Ala | covalently bind penicillin-binding proteins inhibitin the last transpeptidation step in cell wall synthesis
32
B-lactam resistance
structural differences in PBPs decreased PBP affinity for B-lactams inability for drug to reach site of action active efflux pumps drug destruction and inactivation by B-lactamases
33
Natural penicillins spectrum
highly effective against gram + cocci, but easily hydrolyzed by penicillinase
34
natural penicillins therapeutic use
narrow spectrum | strep pneumoniae pneumonia and menigitis
35
penicillin V uses
strep pyogens, strep viridans (endocarditis), syphilis
36
anti-staphylococcal penicillins spectrum
penicllinase resistant thus agents of choice for staph aureus and staph epidermis that are not methicillin resistant
37
anti-staphylococcal penicillins uses
restricted to infections w/known staph sensitivity
38
aminopenicillins spectrum
extended-spectrum frequently administered w/b-lactamase inhibitor gram + and -
39
aminopenicillin uses
URI (S. pyogenes, S. pneumonia, H. influenza) sinusitis otitis media enterococcal infections
40
anti-pseudomonal penicillins spectrum
extends sepctrum to pseudomonas aeruginosa enterobacter proteus
41
anti-pseudomonal penicillins uses
``` serious gram - infections hospital acquired pneumonia immunocompromised bacteremia burn infections UTIs ```
42
penicillin adverse effects
``` allergic rxns anaphylaxis interstitial nephritis (rare) nausea, vomiting, mild-severe diarrhea pseusomembranous colitis ```
43
first generation cephalosproins spectrum
good gram + coverage | modest gram - (moraxella, E. coli, klebsiella pneumoniae, P. mirabilis)
44
first generation cephalosporins uses
skin and soft tissue infections | surgical prophylaxis
45
second generation cephalosporins spectrum
somewhat increased activity against gram -, but less active then 3rd generation subset active against bacteroides fragilis
46
second generation cephalosporins uses
gram neg mixed anaerobic intra-abdominal infections PID diabetic foot infections
47
third generation cephalosporins
less active against gram + more against enterobacteriaceae resistance increasing
48
third generation uses
DOC for serious gram - infections (klebsiella, enterobacter, proteus, providencia, serratia, Haemophilus) DOC for gonorrhea and sever Lyme, meningits
49
fourth generation cephalosporin spectrum
extends beyond 3rd gen psuedomnas
50
fourth generation uses
empirical Tx of nosocomial infections
51
cephlosporins adverse effects
1% cross-reactivity to penicllins diarrhea intolerance to alcohol
52
carbapenems sepctrum
``` aerobic and anaerobic gram + enterobacteriaceae pesugomonas acinetobacter ```
53
resistant to carbapenems
stenotrophomonas maltophilia
54
carbapenem uses
``` UTI LRTIs intra-abdominal gynocological SSTI bone joint ```
55
carbapenem adverse effects
nausea/vomiting seizures hypersensativity
56
monobactam spectrum
``` gram - enterobacteria pseudomonas H. influenza gonococci not against gram + or anaerobes ```
57
monobactam uses
allergic to B-lactams
58
B-lactamases class A
entended spectrum | most worrisome KPC carbapenemase rapidly emerging in enterobacteriaceae
59
B-lactamases class B
Zn dependent enzymess destroys all B-lactams except aztreonam
60
B-lactamases class C
active against cephalosporins
61
B-lactamases calss D
cloxacillin degrading enzymes
62
B-lactamase inhibitors MOA
prevent destruction of B-lactam antibiotics, most active against plasmid encoded bB-lacamases, but inactive against chromosmal B-lactamase induced gram-
63
glycopeptides MOA
inhibits cell wall synthesis binding w/high affinity to D-ala-D-ala target to D-alaynl-D-lactate or D-ananyl-D-serine which binds glycopeptides poorly
64
glycopeptides spectrum
broad gram + | S. aureus, S. epidermidis, strep, bacillus, corynebacterium, actinomuces, clostrdium
65
glycopeptides resistance
gram - | mycobacterium
66
glycopeptides uses
``` osteomyelitis endocardits MRSA strep enterococci CNS infections bacteremia orally for clostridium difficle ```
67
glycopeptides adverse effects
``` macular skin rash, chills, fever, rash red-man syndrome (histamine release) extreme flushing tachycardia hypotension ototoxicity neprhotoxicity ```
68
fluroquinolones MOA
concentration dependent targets bacterial DNA gyrase, topoisomerase IV prevents relaxation of supercoils
69
fluroquinolones resistance
mutation in genes encoding DNA gyrase or topisomerase IV | active transport out of cell
70
fluroquinolones spectrum
``` E. coli salmonella shigella enterobacter campylobacter neisseria pseudomonas S. aureus limited coverage of strep ```
71
fluroquinolones uses
``` UTI prostatitis STI travelers diarrhea shigelllosis bone and joint infections diabetic foot infection ```
72
fluroquinolones adverse effects
``` GI CNS rash, photosensitive, Achilles tendon rupture CI in kids ```
73
30s inhibitors
aminoglycosides | tetracyclines
74
50s inhibitors
macrolides chloramphenicol clindamycin
75
aminoglycosides MOA
concentration dependent binds 30S disrupts protein synthesis exhibit post antibiotic effect
76
aminoglycoside resistance
AG metabolizing enzymes impaired transport of drug into cell altered ribosome
77
aminoglycosides spectrum
aerobic gram - bacteria | limited against gram + synergistic bactericidal effects in gram + w/cell wall active agent
78
Aminoglycoside uses
``` UTI (not uncomplicated) used if resistant to other agents seriously ill pneumonia (Strep and anaerobes) HAP peritonitis synergy in bacterial endocarditis tobramycin inhalation in CF ```
79
aminoglycosides adverse effects
ototoxicity nephrotoxicity neuromuscular block and apnea
80
tetracyclines/glycylcyclines MOA
bacteriostatic inhibits bacterial protein synthesis by binding 30s prevents access of aminoacyl tRNA to acceptor site on mRNA
81
tetracyclines/glyclycyclines resistance
``` decreased influx acquisition of energy dependent efflux ribosomal protection proteins enzymatic inactivation all stains of pseudomonas ```
82
tetracyclin/glycylcyclines spectrum
``` wide range of aerobic and anerobic gram + and gram - rickettsia coxiella burnetii mycoplasma pneumoniae chlamydia legionella atypical mycobacterium plasmodium borrelia burgdorferi treponema pallidum ```
83
tigecycline
no proteus and providencia
84
tetracyclin/glycylcyclines uses
``` CAP atypical CAP community acquired MRSA ance rickettsial infections Q fever anthrax ```
85
tetracyclin/glycylcyclines adverse effects
``` GI superinfections of C. difficile photosensitivity teeth discoloration thrombophlebits ```
86
macrolides/ketolides MOA
bacteriostatic binds reversibly to 50s inhibits translocation
87
macrolides/ketolides resistance
drug efflux ribosomal protection proteins hydrolysis ribosomal mutations
88
macrolides/ketolides uses
``` respiratory infections alternative of otitis media sinusitis bronchitis SSTIs pertussis gastroentertis H. pylori mycobacterium ```
89
macrolides/ketolides drug interactions
CYP3A4 inhibition | prolongs effects of digoxin, warfarin
90
lincosamides MOA
binds 50s
91
lincosamides resistance
ribosomal methylation | all aerobic gram - bacillli
92
lincosamides spectrum
``` penumococci S. pyogens, viridans Streptococci MSSA anerobes (B. fragilis) ```
93
lincosamides uses
``` SSTIs necrotizing SSTIs lung abscesses anaerobic lung and pleural space infections topically for acne vulgaris ```
94
lincosamides adverse effects
``` diarrhea pseudomembranous colitis skin rashes reversible increase in aminotransferase activity potentiate neuromuscular blockade ```
95
Streptogramins MOA
bactericidal, protein synthesis inhibitors, bind 50s
96
streptogramins resistance
ribosomal methylase, acetyltransferase inactivation of dalfopristin
97
streptogramins spectrum
``` gram + cocci s. peumoniae beta and alpha hemolytic strep E. faecium coagulase + and - staph atypical organisms (m. pneumoniae, legionella c. pneumoniae) ```
98
streptogramins uses
vancomycin resistant E. faecium | complicated SSTI by MSSA or S. pyogenes
99
streptogramins adverse effects
infusion related pain and phelbitis | arthralgia and myalgia
100
streptogramins drug interactions
``` CYP3A4 inhibition anticovulsants macrolides some FQs antidepressents ```
101
oxazolidinones MOA
inhibits protein synthesis | 50s
102
oxazolidinones resistance
ribosomal mutation
103
oxazolidinones spectrum
gram + staph, strep, enterococci, anaerobic, gram + rods
104
oxazolidinones uses
VRE faecium nosocomial penumonia due to MSSA and MRSA CAP complicated and uncomplicated SSTI
105
oxazolidinones adverse effects
myelosupression headache rash
106
oxazolidinones drug interactions
weak nonspecific inhibitor of monoamine oxidase
107
inhibitors of cell membrane fnx
polymyxins | lipopeptides
108
polymyxins MOA
interacts w/phospholipids disrupts structure of cell membranes changes permeability
109
polymyxins spectrum
restricted to gram - | enterobacter, E. coli, klebsiella, salmonella, pasteurella, bordetella, shigella, P. aeruginosa, acinetobacter
110
polymyxin resistance
proteus | serratia
111
polymyxin uses
topical, skin, mucous membranes, eye, ear, urinary bladder irrigation, ihalation
112
polymyxin adverse effects
nephrotoxicity | mm weakness and apnea
113
lipopeptides MOA
binds bacterial membranes -> depolarization, loss of membrane potential -> cell death
114
lipopeptides resistance
may be due to changes in cell membrane charge
115
lipopeptides spectrum
bacteriacideal concentration dependent active against aerobic faculagie and anaerobic gram +
116
lipopeptides uses
complicated SSTIs complicated bacteremia right sided endocarditis
117
lipopeptides adverse effects
msk damage elevations in creatine kinase rare rhabdomyolysis
118
metronidazole MOA
prodrug, requires reductive activation of nitro grps by susceptible organisms highly reactive nitro radical anions kill organsims by targeting DNA
119
metronidazole resistance
decreased formation of nitro radicals
120
metronidazole spectrum
``` anaerobic cocci anaerobic gram - bacilli anaerobic spore forming gram + bacilli trichomoniasis amebiasis giardiasis helicobacter campylobacter ```
121
metronidazole uses
``` bacterial vaginosis amebic liver abscess anaerobic bacterial infections bones, joints, CNS C. difficile Chron's disease ```
122
metronidazone adverse effects
HA, dry mouth, metallic taste vomiting, diarrhea, abdominal distress disulfiram effect
123
metronidazone drug interactions
induced meta of phenobarbital, prednisone, rifampin, warfarin
124
sulfonamides MOA
bacteriostatic, competitive inhibitors of dihyropteroate synthase prevents bacterial use of PABA for synthesis of folic acid
125
trimethoprim MOA
inhibition of microbial dihydrofolate reductase
126
sulfonamide and trimethoprim resistance
lower enzyme affinity decrease permeability or active efflux alternative pathway or increased production of folic acid
127
sulfonamide and trimethoprim uses
``` UTI bacterial prostatitis bronchitis shigellosis travelers diarrhea salmonella pneumocystis jiroveci nocardia stenotrphomonas maltophilia DO NOT use in strep pharyngitis ```
128
sulfonamide and trimethoprim adverse effects
``` allergic skin rashes nausea, vomiting CNS (HA and depression) photosensitivity renal dysfnx stevens-johnson syndrome ```
129
sulfonamide and trimethoprim drug interaactions
potentiated effects of warfarin
130
methenamine MOA
decomposes in water to formaldehyde
131
methenamine resistance
nome
132
methenamine spectrum
all bacterial
133
methenamine uses
not primary drug for actue UTI
134
methenamine adverse effects
GI painful and frequent micturition albuminuria, hematuria rashes, low systemic toxicity at usual doses
135
nitrofurantoin MOA
highly reactive intermediates damage DNA | bacteria reduce drug more rapidly than mammalian cells
136
nitrofuantoin uses
UTI | not recommended for pyleonephritis or prostatitis
137
nitrofuantoin adverse effects
nausea, vomiting, diarrhea | course of therapy should not exceed 14 days
138
nitrofuantoin contraindications
pregnant women impaired renal fnx < 1month